argenx to Host Autoimmune Myositis R&D Webinar

argenx to Host Autoimmune Myositis R&D Webinar

June 23, 2026, 7:00 AM CET

Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled "R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis" today, June 23, 2026, at 2:00pm ET.

argenx management and scientific leadership will be joined by external key opinion leaders:

  • Avery LaChance, MD, MPH, FAAD, Associate Professor of Dermatology, Harvard Medical School; Director of Connective Tissue Disease Clinic
  • Arjun Seth, MD, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University Feinberg School of Medicine
  • Rohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh, and Co-Director of UPMC Myositis Center

Webcast Information

A live webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Additional materials, including supporting presentation slides, will be available on argenx's Events & Presentations website today at 2:00pm ET.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:
Colin McBean
cmcbean@argenx.com

Investors:
Alexandra Roy
aroy@argenx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARGX
The Conversation (0)
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 5 Canadian Biotech Stocks in 2026

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here, the Investing News Network profiles the five best-performing Canadian biotech stocks... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks in 2026

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of November 4, the index stood at 7,463.68, up over 30 percent year-to-date. The rise shows that investors are... Keep Reading...
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

Bria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor modelsBriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or... Keep Reading...
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

(TheNewswire) Third pharmaceutical company relationship entered Kelowna, British Columbia November 4, 2026 TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an... Keep Reading...
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

Four presentations highlight BriaCell's Bria-OTS+™ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programsIn vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer modelsBriaPro data describes BP-80... Keep Reading...

Interactive Chart

Latest Press Releases

Related News